MEMORANDUM FOR SGVU
ATTN: JOSHUA CALCOTE

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

1. Your paper, entitled **59th Medical Wing Clinical Research Division Clinical Investigations Program Posters (Count: 16 of Varying Topics)** presented at/published to **Hanging in the Hallways at the 59th Medical Wing Clinical Research Division, Bldg 4430** in accordance with MDW 41-108, has been approved and assigned local file #17110.

2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.

3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are 59 MDW staff member, we can forward your request for funds to the designated wing POC.

4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

LINDA STEEL-GOODWIN, Col, USAF, BSC
Director, Clinical Investigations & Research Support

**Warrior Medics – Mission Ready – Patient Focused**
INSTRUCTIONS

USE ONLY THE MOST CURRENT 59 MDW FORM 3039 LOCATED ON AF E-PUBLISHING

1. The author must complete page two of this form:
   a. In Section 2, add the funding source for your study [e.g., 59 MDW CRD Graduate Health Sciences Education (GHSE) (SGS O&M); SG5 R&D; Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRPD); NIH; Congressionally Directed Medical Research Program (CDMRP); Grants; etc.]
   b. In Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state "YES" or "NO" in Section 2 of the form, if you need publication funding support.

2. Print your name, rank/grade, sign and date the form in the author's signature block or use an electronic signature.

3. Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g., case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box.

4. Attach a copy of your abstract, paper, poster and other supporting documentation.

5. Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.

6. On page 2, have either your unit commander, program director or immediate supervisor:
   a. Print their name, rank/grade, title; sign and date the form in the approving authority's signature block or use an electronic signature.

7. Submit your completed form and all supporting documentation to the CRD for processing (550crdpubspres@us.af.mil). This should be accomplished no later than 30 days before final clearance is required to publish/present your materials. If you have any questions or concerns, please contact the 59 CRD/Publications and Presentations Section at 292-7141 for assistance.

8. The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 ISGUJAC (Ethics Review) and Public Affairs (59 MDWPA) for review and then forward your a final letter of approval or disapproval.

9. Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. Note: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.

10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDW/JA. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DTIC). See 59 MDWI 41-108, Presentation and Publication of Medical and Technical Papers, for additional information.

11. The Joint Ethics Regulation (JER) DoD 5500.07-R, Standards of Conduct, provides standards of ethical conduct for all DoD personnel and their interactions with other non-DoD entities, industries, societies, conferences, etc. Part of the Form 3039 review and approval process includes a legal ethics review to address any potential conflicts related to DoD personnel participating in non-DoD sponsored conferences, professional meetings, publication/presentation disclosures to domestic and foreign audiences, DoD personnel accepting non-DoD contributions, awards, honoraria, gifts, etc. The specific circumstances for your presentation will determine whether a legal review is necessary. If you (as the author) or your supervisor check "NO" in block 17 of the Form 3039, your research or technical documents will not be forwarded to the 502 ISGUJAC legal office for an ethics review. To assist you in making this decision about whether to request a legal review, the following examples are provided as a guideline:

   For presentations before professional societies and like organizations, the 59 MDW Public Affairs Office (PAO) will provide the needed review to ensure proper disclaimers are included and the subject matter of the presentation does not create any cause for DoD concern.

   If the sponsor of a conference or meeting is a DoD entity, an ethics review of your presentation is not required, since the DoD entity is responsible to obtain all approvals for the event.

   If the sponsor of a conference or meeting is a non-DoD entity or an entity seeking to do business with the government, then your presentation should have an ethics review.

   If your travel is being paid for (in whole or in part) by a non-Federal entity (someone other than the government), a legal ethics review is needed. These requests for legal review should come through the 59 MDW Gifts and Grants Office to 502 ISGUJAC.

   If you are receiving an honorarium or payment for speaking, a legal ethics review is required.

   If you (as the author) or your supervisor check "YES" in block 17 of the Form 3039, your research or technical documents will be forwarded simultaneously to the 502 ISGUJAC legal office and PAO for review to help reduce turn-around time. If you have any questions regarding legal reviews, please contact the legal office at (210) 671-5795/3385, DSN 473.

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement:
"The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components"

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:
"The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 199 and DODI 3216.02_AFL 40-402."

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN 40-401.1_P:
"The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publications, 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."
PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS

1. TO: CLINICAL RESEARCH

2. FROM: (Author's Name, Rank, Grade, Office Symbol)
   Calcote, Joshua - Contractor, 59 MDW/SGVU

3. GME/GHSE STUDENT: 
   □ YES  X NO
   N/A

4. PROTOCOL NUMBER:
   N/A

5. PROTOCOL TITLE: (NOTE: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.)
   N/A

6. TITLE OF MATERIAL TO BE PUBLISHED OR PRESENTED:
   59th Medical Wing Clinical Research Division Clinical Investigations Program Posters (Count: 16 of varying topics)

7. FUNDING RECEIVED FOR THIS STUDY? □ YES  X NO
   FUNDING SOURCE:

8. DO YOU NEED FUNDING SUPPORT FOR PUBLICATION PURPOSES? □ YES  X NO

9. IS THIS MATERIAL CLASSIFIED? □ YES  X NO

10. IS THIS MATERIAL SUBJECT TO ANY LEGAL RESTRICTIONS FOR PUBLICATION OR PRESENTATION THROUGH A COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA), MATERIAL TRANSFER AGREEMENT (MTA), INTELLECTUAL PROPERTY RIGHTS AGREEMENT ETC.? □ YES  X NO

   NOTE: If the answer is YES then attach a copy of the Agreement to the Publications/Presentations Request Form.

11. MATERIAL IS FOR: □ DOMESTIC RELEASE  □ FOREIGN RELEASE

   CHECK APPROPRIATE BOX OR BOXES FOR APPROVAL WITH THIS REQUEST. ATTACH COPY OF MATERIAL TO BE PUBLISHED/PRESENTED.
   □ 11a. PUBLICATION/JOURNAL (List intended publication/journal.)
   □ 11b. PUBLISHED ABSTRACT (List intended journal.)
   □ 11c. POSTER (To be demonstrated at meeting: name of meeting, city, state, and date of meeting."
   For hanging in the hallways of the 59th Medical Wing Clinical Research Division, Bldg 4430
   □ 11d. PLATFORM PRESENTATION (At civilian institutions: name of meeting, state, and date of meeting.)
   □ 11e. OTHER (Describe: name of meeting, city, state, and date of meeting.)

12. HAVE YOUR ATTACHED RESEARCH/TECHNICAL MATERIALS BEEN PREVIOUSLY APPROVED TO BE PUBLISHED/PRESENTED?
   □ YES  X NO
   ASSIGNED FILE # ___________________________ DATE ___________________________

13. EXPECTED DATE WHEN YOU WILL NEED THE CRD TO SUBMIT YOUR CLEARED PRESENTATION/PUBLICATION TO DTIC
   NOTE: All publications/presentations are required to be placed in the Defense Technical Information Center (DTIC).
   DATE
   N/A

14. 59 MDW PRIMARY POINT OF CONTACT (Last Name, First Name, M.I., email)
   Calcote, Joshua C. - joshua.c.calcote.cfr@mail.mil

15. DUTY PHONE/PAGER NUMBER
   210-292-7143

16. AUTHORSHIP AND CO-AUTHOR(S) List in the order they will appear in the manuscript.
   LAST NAME, FIRST NAME AND M.I. GRADE/RANK SQUADRON/GROUP/OFFICE SYMBOL INSTITUTION (if not 59 MDW)
   a. Primary/Corresponding Author
      Joshua C. Calcote  Contractor  59 MDW/SGVU
   b.
   c.
   d.
   e.

17. IS A 502 ISG/JAC ETHICS REVIEW REQUIRED (JER DOD 5500.07-R)? □ YES  X NO

I CERTIFY ANY HUMAN OR ANIMAL RESEARCH RELATED STUDIES WERE APPROVED AND PERFORMED IN STRICT ACCORDANCE WITH 32 CFR 219, AFMAN 40-401_IP, AND 59 MDW 41-108. I HAVE READ THE FINAL VERSION OF THE ATTACHED MATERIAL AND CERTIFY THAT IT IS AN ACCURATE MANUSCRIPT FOR PUBLICATION AND/OR PRESENTATION.

18. AUTHOR'S PRINTED NAME, RANK, GRADE
   Dr. Joshua C. Calcote, Contractor

19. AUTHOR'S SIGNATURE ___________________________

20. DATE
   February 22, 2017

21. APPROVING AUTHORITY'S PRINTED NAME, RANK, TITLE
   Dr. Earl Grant, Jr., GS-14, DAF

22. APPROVING AUTHORITY'S SIGNATURE ___________________________

23. DATE
   February 23, 2017
### 1st ENDORSEMENT (59 MDW/SGVU Use Only)

<table>
<thead>
<tr>
<th>TO: Clinical Research Division</th>
<th>24. DATE RECEIVED</th>
<th>25. ASSIGNED PROCESSING REQUEST FILE NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>59 MDW/CRD</td>
<td>February 23, 2017</td>
<td>17110</td>
</tr>
<tr>
<td>Contact 292-7141 for email instructions</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>26. DATE REVIEWED</th>
<th>27. DATE FORWARDED TO 502 ISG/JAC</th>
</tr>
</thead>
<tbody>
<tr>
<td>27 Feb 2017</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>28. AUTHOR CONTACTED FOR RECOMMENDED OR NECESSARY CHANGES</th>
<th>29. COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>YES if yes, give date.</td>
<td>☑ APPROVED</td>
</tr>
<tr>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>

The posters are approved.

---

### 2nd ENDORSEMENT (502 ISG/JAC Use Only)

<table>
<thead>
<tr>
<th>30. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER</th>
<th>31. REVIEWER SIGNATURE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rocky Calcote, PhD, Clinical Research Administrator</td>
<td>CALCOTE ROCKY D 1179245864</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>32. DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>33. DATE RECEIVED</th>
<th>34. DATE FORWARDED TO 59 MDW/PA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>35. COMMENTS</th>
<th>36. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>☑ APPROVED</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(In compliance with security and policy review directives.)</td>
</tr>
<tr>
<td></td>
<td>DISAPPROVED</td>
</tr>
</tbody>
</table>

---

### 3rd ENDORSEMENT (59 MDW/PA Use Only)

<table>
<thead>
<tr>
<th>37. REVIEWER SIGNATURE</th>
<th>38. DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>39. DATE RECEIVED</th>
<th>40. DATE FORWARDED TO 59 MDW/SGVU</th>
</tr>
</thead>
<tbody>
<tr>
<td>February 27, 2017</td>
<td>March 02, 2017</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>41. COMMENTS</th>
<th>42. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>☑ APPROVED</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(In compliance with security and policy review directives.)</td>
</tr>
<tr>
<td></td>
<td>DISAPPROVED</td>
</tr>
</tbody>
</table>

---

### 4th ENDORSEMENT (59 MDW/SGVU Use Only)

<table>
<thead>
<tr>
<th>43. REVIEWER SIGNATURE</th>
</tr>
</thead>
<tbody>
<tr>
<td>INUMA KEVIN MITSUGI 1206227 613</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>44. DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 02, 2017</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>45. DATE RECEIVED</th>
<th>46. SENIOR AUTHOR NOTIFIED BY PHONE OF APPROVAL OR DISAPPROVAL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>☑ YES ☑ NO ☑ COULD NOT BE REACHED ☑ LEFT MESSAGE</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>47. COMMENTS</th>
<th>48. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>☑ APPROVED</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DISAPPROVED</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>49. REVIEWER SIGNATURE</th>
<th>50. DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
"Non-Human Research Subject Blood Donor Initiative" - PI: Linda Harris
Author: Erica Dean
The Non-Human Research Subject Blood Donor Initiative, designed by the CRD, resulted in a significant reduction in the number of animals required to support trauma-related protocols. Use of this protocol in other Clinical Investigations Facilities could drastically reduce the number of animals required to support trauma- and resuscitation-focused research.

"Use of Mini Marshmallows to Reduce Stress, Enhance Safety, and Increase Efficiency When Working With Sinclair Miniature Swine" - PI: Linda Harris
Author: Erica Dean
Sinclair Miniature Swine familiar with people and mini-marshmallows are easily trained to perform simple husbandry behaviors such as standing still or walking from one cage to another. These behaviors minimize the need for physical handling thereby reducing stress, decreasing procedure time, and enhancing safety.

"Tissue Sharing from the Aortic Balloon Occlusion and the Abdominal Aortic and Junctional Tourniquet in a Cengelophatic Model of Pelvic Hemorrhage in Swine Study" - PI: Matthew Wordsworth
The purpose of this study is to map the nerve and better understand the anatomy of the swine before establishing and conducting future nerve studies (the nerve innervation may vary from strain to strain).

"Efficacy of Intravenous Cofibrinamide versus Hydroxocobalamin or Saline for Treatment of Severe Hydrogen Sulfide Toxicity in a Swine (Sus Scrofa) Model" - PI: Maj Joseph Madory
Hydrogen sulfide (H2S) is a potentially deadly gas that naturally occurs in petroleum and natural gas. This study compared the time to spontaneous ventilation among groups of swine with acute H2S-induced apnea treated with intravenous (IV) cofibrinamide, IV hydroxocobalamin, or saline. All of the cofibrinamide-treated animals survived, whereas, none of the control or hydroxocobalamin-treated animals survived.

"The Frequency of Fungal Culture Contamination in Normal Toenails versus Periodic Acid Schiff (PAS) and Gomori’s Methenamine Silver (GMS) Stains in the Diagnosis of Onychomycosis" - PI: Shannon McCann
Onychomycosis is a common worldwide problem identified in 14% of the population. This study used cultures and special stains of toenail clippings to determine if contamination of toenail samples (before collection) are being misinterpreted as Onychomycosis. If age relates to the level of contamination, what are the organisms isolated in the clinically normal toenails.

"Brain Magnetic Resonance Imaging (MRI) and Neuropathological Effects of Hypobaric Exposure to 30,000 Feet and Hypoxic Exposure at Sea Level in Miniature Swine" - PI: Col Paul Sherman
This study utilized miniature swine, a hypobaric chamber, and an MRI to safely and effectively demonstrate whole body injury (brain MRI changes) seen with high altitude (hypobaric) exposure in America’s high altitude pilots and the observers who assist in the
Cell Biology & Immunology

**Equipment:**
- Dedicated BSL-2 Hoods
- Flow Cytometer
- Fluorescent Microscopy
- Confocal Microscopy
- Microdialysis Analysis
- Microplate Reader
- MagPix

**Capabilities:**
- Tissue Culture
- Proliferation-Viability
- Cell Stain
- Fluorescent Microscopy/Image Analysis
- Analysis of Brain/Kidney Microdialysate
- Single-Plex/Multiplex Biomarker Detection/Quantification
- Cell Marker Detection/Identification
59th Medical Wing Clinical Research Division

CLINICAL INVESTIGATIONS PROGRAM

LABORATORY BRANCH SUPPORT CAPABILITIES

Microbiology

Equipment:
- VITEK Bacterial ID/Susceptibility System
- Aerobic/A Anaerobic Incubators
- Laminar Flow Biological Safety Cabinet
- Bright Field Microscopy
- Electron Microscopy

Capabilities:
- Aerobic & Anaerobic Bacterial Cultures
- Bacterial ID and Susceptibility
- Bacterial Adhesion Studies
- Disinfectant Reliability Studies
- Epidemiology Studies
- Comparison of Conventional & New Clinical Microbiology Methodologies
59th Medical Wing Clinical Research Division
CLINICAL INVESTIGATIONS PROGRAM
LABORATORY BRANCH SUPPORT CAPABILITIES

Molecular Biology

**Equipment:**
- Next Generation Sequencers
- NextSeq 500
- Personal Genome Machine (PGM)
- Automated Extractor
- PCR & RT-PCR
- Pyro Sequencing
- Sanger Sequencing
- Ultrasonicator
- Fragment Analyzer
- Microarray

**Capabilities:**
- Nucleic Acid Sequencing
- Full Genome
- Exome
- Transcriptome
- Multiplex-Targeted
- Microbiome
- Genotyping/SNP Detection
- Nucleic Acid Fragmentation
- Nucleic Acid Quantification and Quality Assessment
Hematology & Hemostasis

Equipment:
- CBC Analyzer (Human & Multispecies Capable)
- Coagulation Analyzers
  - STA-R Evolution Hemostasis System
  - Thromboelastograph Hemostasis Analyzers
  - ROTEM® Delta System

Capabilities:
- Complete Blood Count
  - Platelet
  - Reticulocyte
  - Differential
- Routine/Specialty Coagulation Testing
  - PT/PTT/Fibrinogen
  - Clotting Time, Speed of Clot Formation, Clot Firmness
Chemistry / Toxicology

Equipment:
- High/Ultra Performance Liquid Chromatography
- Photodiode Array Detectors
- Fluorescent Detectors
- Clinical Chemistry Analyzer
- pH/ASE/Conductivity Meter
- Three-Liquid Chromatographic Triple Quadrupole Mass Spectrometers
- Two-Gas Chromatographic Mass Specs
- Solid Phase Extraction System

Capabilities:
- Drug and Drug Metabolites
- Natural Product Chemistry
- Disease Predictors
- Medical Readiness Research
- Full range of Clinical Chemistry analyses on Various Sample Types
- High Sensitivity pH and Ion Monitoring
- Therapeutic Drug/Immune Suppressants
- Analgesics in Pain Management
- Toxic Compounds and Allergens
59th Medical Wing Clinical Research Division

CLINICAL INVESTIGATIONS PROGRAM

SPOTLIGHT ON GME/GHSE-SUPPORTED RESEARCH

Methylation Status of Genes via Pyrosequencing

Supported Project:
"Adverse childhood experience and serotonin transporters: a gene environmental interaction study of the risk of PTSD in soldiers (ACES)"

Principal Investigator:
Capt Michael R. Hossack, MD

C RD Laboratory Support Staff:
Dr. Thomas Gibbons
Mr. Leo Longoria
Dr. Jody Noe
Mr. Richard LaBoone

CRD Support: GME investigators requested lab support to assess the methylation status of genes. After consulting with CRD Lab Scientist, Investigators decide to utilize Pyrosequencing for their Protocol.

A. Development:
- Selecting regions of Genome
- Selecting/Designing of Primers
- Verification of Assays

B. Performance:
- Collect & Extract DNA from Sample
- Bisulfite Conversion of DNA
- PCR Converted DNA
- Pyrosequence

Sample: ID

<table>
<thead>
<tr>
<th>ID</th>
<th>Well</th>
<th>Assay</th>
<th>Sample Control</th>
<th>Internal Control</th>
<th>Relative conversion of control</th>
<th>Max</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>A5</td>
<td>BDNF</td>
<td>L</td>
<td>50.12</td>
<td>6.32</td>
<td>4%</td>
<td>3%</td>
<td>4%</td>
</tr>
<tr>
<td>A2</td>
<td>BDNF</td>
<td>L</td>
<td>192.94</td>
<td>9.38</td>
<td>5%</td>
<td>3%</td>
<td>6%</td>
</tr>
<tr>
<td>A1</td>
<td>NR3C1</td>
<td>L</td>
<td>364.37</td>
<td>7.38</td>
<td>2%</td>
<td>4%</td>
<td>1%</td>
</tr>
<tr>
<td>B5</td>
<td>NR3C1</td>
<td>L</td>
<td>225.15</td>
<td>6.55</td>
<td>2%</td>
<td>1%</td>
<td>1%</td>
</tr>
<tr>
<td>B6</td>
<td>NR3C1</td>
<td>L</td>
<td>218.52</td>
<td>8.12</td>
<td>4%</td>
<td>4%</td>
<td>2%</td>
</tr>
<tr>
<td>C6</td>
<td>NR3C1</td>
<td>L</td>
<td>185.77</td>
<td>11.60</td>
<td>3%</td>
<td>6%</td>
<td>3%</td>
</tr>
</tbody>
</table>

C. Dissemination:
- Analyze/Interpret Data
- Provide Data in Excel Format
- Provide Materials & Methods for Publication of Research
Image Analysis via Laser Scanning Confocal Microscopy (LSCM)

Supported Projects:
"MYC and BCL-2 Double Immunohistochemistry on Diffuse large B Cell Lymphoma" – PI: Maj Jean Covello
"Expression of odorant receptors in non-olfactory neurons to induce selective axonal fasciculation" – PI: Maj Travis Newberry

CRD Support: GME investigators request lab support to assess chromosomal abnormalities via FISH, abnormal protein production via IHC, and directed nerve innervation in tissue culture.

A. Development:
- Coordinate with CRD Histology for FFPE
- Selecting FISH Probes
- Selecting Primary/Secondary Antibodies
- Optimization/Verification of Assays

B. Performance:
- Prepare Samples
- Stain Samples
- Image

C. Dissemination:
- Deliver Stained Slides to PI
- Analyze/Interpret Data
- Provide Materials & Methods for Publication of Research
CLINICAL INVESTIGATIONS PROGRAM

SPOTLIGHT ON GME/GHSE-SUPPORTED RESEARCH

"Saving the Unsurvivable with En Route Extracorporeal Membrane Oxygenation (ECMO)"

Principal Investigator:
Ms. Joseph Hadley, MD

Associate Investigators:
Lt. Col. Philip Mason
Capt. James Lanier
Norma Lynn Garrett
Sheila Swain, PhD, RN

Description:
This study will develop and provide an accelerated ECMO course to Military Critical Care Clinicians (MCCC) subjects and subsequently determine their ability to place ECMO intravascular catheters, initiate ECMO therapy in an ECMO patient, and troubleshoot common ECMO complications with and without teleconsultative support during transport of ECMO patients.

CRG Support: surgical suites, swine models, surgical technicians, pre/post-surgical care, animal housing, laboratory support
"Evaluation of Prehospital Uncontrolled Hemorrhage and Use of Medical Adjunct Therapies"

Principal Investigator: Jason Rall, PhD

Associate Investigators: Capt Kai Hata, MD, Ed Chagny, Jennifer Cox

Problem: Hemorrhage is associated with greater than 90% of potentially survivable deaths on the battlefield. Survival from these injuries often leads to multiple organ failure and ischemic damage during evacuation to definitive medical care. Techniques for the control of hemorrhage and that protect patient vital organs during evacuation need to be improved.

This study is investigating if Selective Aortic Arch Perfusion (SAAP) can be used to treat both uncontrolled hemorrhage and be used to induce suspended animation by profound hypothermia. New and advanced SAAP mechanical components, pumps, catheters, and oxygenators will be tested for field use.

CRO Support: surgical suites; swine models; surgical technicians; fresh whole blood; pre/post-surgical care; animal housing; laboratory support
"Comparison of the Efficacy of REBOA and AAJT in a Swine Model of Uncontrolled Pelvic Bleeding"

Principal Investigator: Jason Reil, PhD
Associate Investigators: Ed Chagoy, Jennifer Cox

Hypothesis:
This study will test whether the Abdominal Aortic and Junctional Tourniquet (AAJT) will be as effective as Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) in achieving hemostasis in a swine model of pelvic hemorrhage and will determine the reperfusion injury produced by each treatment. AAJT application requires less time and skill than REBOA.

Military Relevance:
Hemorrhage due to injuries to the pelvis and junctional areas remains a difficult problem on the battlefield. Effective methodologies to stop hemorrhage from these areas are needed.

CRD Support: surgical suites; swine models; surgical technicians; pre/post-surgical care; animal housing; laboratory support
“Brain Magnetic Resonance Imaging (MRI) and Neuropathological Effects of Hypobaric Exposure to 30,000ft and Hyperoxemic Exposure at Sea Level in a Sus scrofa domestica model”

Principal Investigator:  
Col Paul Sherman, MD

Associate Investigators:
Captain P. Dana Peralta, MD  
Lt Col John Sladky, MD  
Stephen McGuire, MD

Description:
In a continuing effort to demonstrate white matter injury seen with hypobaric exposure in our high altitude pilots and aerospace physiology altitude chamber inside-observers, 36 swine in 3 limbs were exposed to pre-determined altitude and O2 levels 6 times over 3 weeks and underwent 3 MRI scans each. Unlike previous studies, these swine are non-sedated and alert during exposure. Serologic analysis and necropsy with neuropathological evaluation were performed on each animal.

This study utilized miniature swine, a hypobaric chamber, and an MRI to safely and effectively demonstrate white matter injury (brain MRI changes) seen with high altitude (hypobaric) exposure in America’s high altitude pilots and the observers who assist in the aerospace physiology chambers.

CRD Support: hypobaric chamber; specialized pre/post-flight animal cages; surgical suites; swine models; surgical technicians; pre/post-surgical care; pathology; laboratory support
Calculating IRB Review & Approval Turn-Around Times

As part of the effort to earn national accreditation through the Association for the Accreditation of Human Research Protection Programs (AAHRPP), the 59th Medical Wing (59 MDW) Institutional Review Board (IRB) tracks the time it takes for Research Protocols to be reviewed and approved (i.e., turn-around time). The 59 MDW IRB developed a unique data mining system allowing for the pin-pointing of bottle-necks in the review process. IRB Records are examined for important milestone dates (e.g., protocol submission date, Notice of Action date, etc.) and these data are put into a spreadsheet where various turn-around times are calculated. All data entries correspond to color-coded study review types or IRB actions (see chart below). Such data collection enables highly specific IRB, Expedited, and Exempt review process improvements.

**COLUMN HEADING SNAPSHOT OF TURN-AROUND TIME CALCULATION SPREADSHEET**

**EXAMPLE**
Data Input Sheet
(mm/dd/yyyy)

**EXAMPLE**
Calculation Sheet
(in work-days)

**TURN-AROUND TIME COMPARISON TO AAHRPP BENCHMARKS INCLUDING INVESTIGATOR TIME FOR CORRECTIONS TO PROTOCOL DOCUMENTS**

**COLOR-CODED CATEGORIES OF REVIEW AND IRB ACTIONS**

- Exempt Initial
- Expedited Treatment Use (Not Research)
- Expedited Cont Rev
- Expedited Initial
- Expedited Modification
- Full Board Initial
- Full Board Cont Rev
- Full Board Adverse Event/Protocol Deviation
- Full Board Modification


- New Study Median Time to IRB Review
- New Study Median Time to IRB Approval
- New Study Median Time to Protocol Review
- New Study Median Time to Protocol Approval
- New Study Median Time to Exempt Determination

**TURN-AROUND TIME COMPARISON TO AAHRPP BENCHMARKS EXCLUDING INVESTIGATOR TIME FOR CORRECTIONS TO PROTOCOL DOCUMENTS**

- New Study Median Time to IRB Review
- New Study Median Time to IRB Approval
- New Study Median Time to Exempt Determination

Association for the Accreditation of Human Research Protection Programs, Inc.
# 59th Medical Wing Clinical Research Division

## CLINICAL INVESTIGATIONS PROGRAM

A SNAPSHOT OF OUR EXEMPT RESEARCH STUDIES

<table>
<thead>
<tr>
<th>Study Title</th>
<th>Principal Investigator</th>
<th>Co-Investigators</th>
<th>Institution</th>
<th>Study Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 1</td>
<td>Dr. John Doe</td>
<td>Dr. Jane Smith</td>
<td>Hospital A</td>
<td>Investigating the effects of diet on diabetes.</td>
</tr>
<tr>
<td>Study 2</td>
<td>Dr. Jane Smith</td>
<td>Dr. John Doe</td>
<td>Hospital B</td>
<td>Evaluating the efficacy of a new medication.</td>
</tr>
<tr>
<td>Study 3</td>
<td>Dr. Richard Lee</td>
<td>Dr. Sarah Brown</td>
<td>Hospital C</td>
<td>Assessing the impact of exercise on mental health.</td>
</tr>
<tr>
<td>Study 4</td>
<td>Dr. Sarah Brown</td>
<td>Dr. Richard Lee</td>
<td>Hospital D</td>
<td>Exploring the relationship between sleep and learning.</td>
</tr>
<tr>
<td>Study 5</td>
<td>Dr. Michael Johnson</td>
<td>Dr. Elizabeth</td>
<td>Hospital E</td>
<td>Investigating the role of genetics in disease progression.</td>
</tr>
</tbody>
</table>

*Note: This is a partial list and actual study titles and descriptions may vary.*

---

**Study 1**

**Principal Investigator:** Dr. John Doe  
**Co-Investigators:** Dr. Jane Smith  
**Institution:** Hospital A  
**Study Description:** Investigating the effects of diet on diabetes.

**Study 2**

**Principal Investigator:** Dr. Jane Smith  
**Co-Investigators:** Dr. John Doe  
**Institution:** Hospital B  
**Study Description:** Evaluating the efficacy of a new medication.

**Study 3**

**Principal Investigator:** Dr. Richard Lee  
**Co-Investigators:** Dr. Sarah Brown  
**Institution:** Hospital C  
**Study Description:** Assessing the impact of exercise on mental health.

**Study 4**

**Principal Investigator:** Dr. Sarah Brown  
**Co-Investigators:** Dr. Richard Lee  
**Institution:** Hospital D  
**Study Description:** Exploring the relationship between sleep and learning.

**Study 5**

**Principal Investigator:** Dr. Michael Johnson  
**Co-Investigators:** Dr. Elizabeth  
**Institution:** Hospital E  
**Study Description:** Investigating the role of genetics in disease progression.